X | ||||||||||
- Definition The percentage of additional transaction fees payable on gross proceeds if any financing completed with in 60 days of present financing. No definition available.
|
X | ||||||||||
- Definition Represents the percentage of advisory fee payable on gross proceeds received from private placements. No definition available.
|
X | ||||||||||
- Definition Amount of bonus payments approved. No definition available.
|
X | ||||||||||
- Definition The amount of professional fees and other offering costs. No definition available.
|
X | ||||||||||
- Definition The amount of transaction cots incurred. No definition available.
|
X | ||||||||||
- Definition Amount of acceleration to license fee payable, due to stock offering through private placement. No definition available.
|
X | ||||||||||
- Definition The maximum percentage of liquidated damages on gross proceeds of financing. No definition available.
|
X | ||||||||||
- Definition The minimum number of days for happening any other financing other than 2021 financing. No definition available.
|
X | ||||||||||
- Definition The cash inflow associated with the net amount received from entity's raising of capital via private rather than public placement. No definition available.
|
X | ||||||||||
- Definition The number of warrants issued for shares. No definition available.
|
X | ||||||||||
- Definition Period For Payment Of Remaining Outstanding Balance Of License Fee. No definition available.
|
X | ||||||||||
- Definition The amount of milestone payments to be incurred for the approval of license. No definition available.
|
X | ||||||||||
- Definition Term of pharmaceutical license agreement in years. No definition available.
|
X | ||||||||||
- Definition The percentage of transfer price on sale of products. No definition available.
|
X | ||||||||||
- Definition The percentage of transaction fees payable on gross proceeds and out of pocket expenses received from financing. No definition available.
|
X | ||||||||||
- Definition Per unit price at which the units are issued by the company under the stock offering. No definition available.
|
X | ||||||||||
- Definition Exercise price per share or per unit of warrants or rights outstanding. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
X | ||||||||||
- Definition Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
X | ||||||||||
- Definition The cash inflow associated with the amount received from entity's raising of capital via private rather than public placement. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
X | ||||||||||
- Definition Number of new stock issued during the period. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
X | ||||||||||
- Definition Ratio applied to the conversion of stock split, for example but not limited to, one share converted to two or two shares converted to one. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
X | ||||||||||
- Definition Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event. No definition available.
|
X | ||||||||||
- Definition Period between issuance and expiration of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
|
X | ||||||||||
- Details
|
X | ||||||||||
- Details
|
X | ||||||||||
- Details
|
X | ||||||||||
- Details
|